Cost-Effectiveness of Preimmunization Hepatitis B Screening in High-Risk Adolescents

Blostein, Joel

doi:10.1093/phr/116.2.165

Cited by 6 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, most of the cost‐effectiveness studies for screening and vaccinating for hepatitis B have focused on infants, children or selected high‐risk groups (25, 57, 58). There are only a few studies (12, 59) focusing on the immigrant population.…”

Section: Discussionmentioning

confidence: 99%

Cost effectiveness of screening immigrants for hepatitis B

Wong

Heathcote

Krahn

2011

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cost effectiveness of screening immigrants for hepatitis B

Wong

Heathcote

Krahn

2011

Liver International

View full text Add to dashboard Cite

show abstract

“…However, vaccination of a person immune to HBV infection because of prior vaccination or infection does not increase the risk for adverse events. Testing is not indicated before vaccination of adolescents or younger children because of the low prevalence of HBV infection in these age groups (9,148).…”

Section: Testing For Hbv Infectionmentioning

confidence: 99%

Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings

Weinbaum¹,

Lyerla²,

Margolis³

2003

PsycEXTRA Dataset

View full text Add to dashboard Cite

This report consolidates previous recommendations and adds new ones for the prevention and control of infections with hepatitis viruses in correctional settings. These recommendations provide guidelines for juvenile and adult correctional systems regarding 1) identification and investigation of acute viral hepatitis; 2) preexposure and postexposure immunization for hepatitis A and hepatitis B; 3) prevention of hepatitis C virus infection and its consequences; 4) health education; and 5) release planning. Implementation of these recommendations can reduce transmission of infections with hepatitis viruses among adults at risk in both correctional facilities and the outside community. These recommendations were developed after consultation with other federal agencies and specialists in the fields of corrections, correctional health care, and public health at a meeting in Atlanta, March 5-7, 2001. This report can serve as a resource for correctional health, corrections, and public health professionals involved in planning and implementing health-care programs for incarcerated persons. Definitions Adolescent: Person aged >10 and <19 years. Adult: Person aged >19 years. Anti-HAV: Total antibody to hepatitis A virus (HAV) detected in serum of persons with acute or resolved HAV infection; indicates a protective immune response to infection, vaccination, and passively acquired antibody. Anti-HBc: Antibody to hepatitis B core antigen; positive test indicates past or current infection with HBV. Anti-HBs: Antibody to hepatitis B surface antigen; indicates immunity to HBV infection, either from HBV infection or immunization. Anti-HCV: Antibody to HCV; positive test indicates past or current infection with HCV. Arrestee: Person placed under arrest by law enforcement who has not been formally charged with a crime. MMWR January 24, 2003 TABLE 1. Estimated chronic infections with hepatitis viruses among inmates and releasees-United States, 1997 Chronic infection Hepatitis B virus Hepatitis C virus Source: Adapted from National Commission on Correctional Health Care. The health status of soon-to-be-released inmates: a report to Congress, 2002. Available at http://www.ncchc.org/pubs_stbr.html. * Based on 1.7 million inmates in prisons and jails, 1997 (15). † Based on estimated 7.75 million unduplicated released inmates (2); A.

show abstract

“…When serology costs less than vaccination, there is always a break-even seroprevalence rate above or below which pre-vaccination screening reduces or increases costs. 7 One assessment of adult travelers found that screening reduced costs. 8 Another study showed that when vaccine was purchased at a lower public sector price and vaccination candidates were younger, screening increased costs.…”

mentioning

confidence: 99%

“…9 Pre-vaccination screening also has been shown to increase costs when serology expenses are higher. 10 For adult hepatitis B immunization, screening reduces costs only when seroprevalence exceeds 17%, 7 a rate several times the U.S. population norm. 4 The availability of a bivalent vaccine provides an opportunity to reduce hepatitis A and B infections among adults but complicates the question of whether to conduct pre-vaccination screening.…”

mentioning

confidence: 99%

“…Prior examinations of pre-vaccination screening assumed that all patients would complete the vaccination series. [7][8][9][10][11] In fact, some patients do not return when vaccination is deferred pending serology results, 6 thereby incurring screening costs but no benefits. Further, populations differ with respect to compliance with subsequent doses, and the probability of protection with an incomplete series differs between recipients of hepatitis A and B vaccines.…”

mentioning

confidence: 99%

See 1 more Smart Citation